Prof. Dr. Tilman Brummer

10 selected publications:

• BRAF inhibition upregulates a variety of receptor tyrosine kinases and their downstream effector Gab2 in colorectal cancer cell lines.
  Herr R*, Halbach S, Heizmann M, Busch H, Boerries M, Brummer T* (2018).
  Oncogene. 37(12):1576-1593.
  *Co-corresponding authors
• The atypical kinase RIOK1 promotes tumor growth and invasive behavior.
  Weinberg F, Reischmann N, Fauth L, Taromi S, Mastroianni J, Köhler M, Halbach S, Becker AC, Deng N, Schmitz T, Uhl FM, Herbener N, Riedel B, Beier F, Swarbrick A, Lassmann S, Dengjel J, Zeiser R, Brummer T (2017).
  EBioMedicine. 20:79-97.
• Discrete cytosolic macromolecular BRAF complexes exhibit distinct activities and composition.
  Diedrich B, Rigbolt KT, Röring M, Herr R, Kaeser-Pebernard S, Gretzmeier C, Murphy RF, Brummer T*, Dengjel J* (2017).
  EMBO J. 36(5):646-663.
  *Co-senior authors
• Recurrent MET fusion genes represent a druggable target in pediatric glioblastoma.
  Bender S, Gronych J, Warnatz HJ, Hutter B, Gröbner S, Ryzhova M, Pfaff E, Hovestadt V, Weinberg F, Halbach S, Kool M, Northcott PA, Sturm D, Bjerke L, Zichner T, Stütz AM, Schramm K, Huang BD, Buchhalter I, Heinold M, Risch T, Worst B, van Tilburg CM, Weber UD, Zapatka M, Raeder B, Milford D, Heiland S, von Kalle C, Previti C, Lawerenz C, Kulozik AE, Unterberg A, Witt O, von Deimling A, Capper D, Truffaux N, Grill J, Jabado N, Sehested AM, Sumerauer D, Hmida-Ben Brahim D, Trabelsi S, Ng, HK, Zagzag D, Allen J, Karajannis MA, Gottardo N, Jones C, Korbel JO, Schmidt S, Wolf S, Reifenberger G, Felsberg J, Brors B, Herold-Mende C, Lehrach H, Brummer T, Korshunov A, Eils R, Yaspo ML, Pfister SM, Lichter P, Jones DTW for the International Cancer Genome Consortium PedBrain Tumor Project (2016). Nature Medicine 22, 1314-1320.
  This publication was highlighted in the “Research Watch” section of Cancer Discovery.
• Gab2 is essential for Bcr-Abl-mediated leukemic transformation and hydronephrosis in a chronic myeloid leukemia mouse model.
  Halbach S, Köhler M, Uhl FM, Huber J, Zeiser R, Koschmieder S, Aumann K*, Brummer T* (2016).
  Leukemia. 30(9):1942-5
  *Co-senior authors.
• Activation loop phosphorylation regulates B-Raf in vivo and transformation by B-Raf mutants.
  Köhler M, Röring M, Schorch B, Heilmann K, Stickel N, Fiala GJ, Schmitt LC, Braun S, Ehrenfeld S, Uhl FM, Kaltenbacher T, Weinberg F, Herzog S, Zeiser R, Schamel WW, Jumaa H, Brummer T. (2016)
  EMBO J. 35(2):143-61.
  This publication was highlighted by a News & Views commentary in the same issue of The EMBO Journal.
• B-Raf inhibitors induce epithelial differentiation in BRAF-mutant colorectal cancer cells.
  Herr R, Köhler M, Andrlová H, Weinberg F, Möller Y, Halbach S, Lutz L, Mastroianni J, Klose M, Bittermann N, Kowar S, Zeiser R, Olayioye MA, Lassmann S, Busch H, Boerries M, Brummer T. (2015)
  Cancer Res. 75(1):216-29.
• BRAF inhibitor-associated ERK activation drives development of chronic lymphocytic leukemia.
  Yaktapour N, Meiss F, Mastroianni J, Zenz T, Andrlova H, Mathew NR, Claus R, Hutter B, Fröhling S, Brors B, Pfeifer D, Pantic M, Bartsch I, Spehl TS, Meyer PT, Duyster J*, Zirlik K*, Brummer T*, Zeiser R*. (2014)
  J Clin Invest. 124(11):5074-84
  *Co-senior authors.
  This publication was highlighted in the section “The attending physician” in the same issue of JCI and in Cancer Discovery.
• Gab2 signaling in chronic myeloid leukemia cells confers resistance to multiple Bcr-Abl inhibitors.
  Wöhrle FU, Halbach S, Aumann K, Schwemmers S, Braun S, Auberger P, Schramek D, Penninger JM, Lassmann S, Werner M, Waller CF, Pahl HL, Zeiser R, Daly RJ, Brummer T (2013).
  Leukemia 27: 118-129
• Distinct requirement for an intact dimer interface in wild-type, V600E and kinase-dead B-Raf signalling.
  Röring M, Herr R, Fiala GJ, Heilmann K, Braun S, Eisenhardt AE, Halbach S, Capper D, von Deimling A, Schamel WW, Saunders DN, Brummer T (2012)
  EMBO J 31: 2629-2647
  This work was featured as a Research Highlight in the June 2012 issue of Nature Reviews Cancer.